Barbaros AYDIN, Senem ALANYALI, Ayfer HAYDAROĞLU, Derya DEMIR, Necmettin ÖZDEMIR, Osman ZEKIOĞLU, Levent YENIAY, Gül KITAPÇIOĞLU

Expression of Cyclin D1 and Its Relationship to Hormone Receptors and Survival in Breast Cancer

The aim of the present study was to evaluate rate of cyclin D1 expression and examine its relationship to clinicopathological factors and impact on prognosis in breast cancer patients.METHODSTotal of 85 estrogen receptor (ER)-positive breast cancer patients were included. Expression of cyclin D1, ER, progesterone receptor (PR), and Ki-67 were determined using immunohistochemistry evaluation.RESULTSPatients’ median age was 49 years (range: 27–83 years) and cyclin D1 was positive in 90.5% of the patients. Cyclin D1 expression was positively correlated with rate of ER positivity and Ki-67 expression (r=0.4; p

PDF

___

http://www.cancer.org/acs/groups/content/@research/ documents/document/acspc-047079.pdf. Accessed November 21, 2016.).
Whelan TJ, Julian J, Wright J, Jadad AR, Levine ML. Does locoregional radiation therapy improve sur- vival in breast cancer? A meta-analysis. J Clin Oncol 2000;18(6):1220–9.
Recht A, Come SE, Henderson IC, Gelman RS, Silver B, Hayes DF, et al. The sequencing of chemotherapy and radiation therapy after conservative surgery for early- stage breast cancer. N Engl J Med 1996;334(21):1356– 61.
Goldhirsch A, Wood WC, Gelber RD, Coates AS, Thürlimann B, Senn HJ. Progress and promise: high- lights of the international expert consensus on the primary therapy of early breast cancer. Ann Oncol
Sİrlie T, Perou CM, Tibshirani R, Aas T, Geisler S, Johnsen H, et al. Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci USA 2001;98(19):10869–74.
Tonini G, Schiavon G, Fratto ME, Vincenzi B, Santini D. Hormono-biological therapy in metastatic breast cancer: preclinical evidence, clinical studies and future directions. Expert Opin Biol Ther 2008;8(2):221–34.
Arnold A, Papanikolaou A. Cyclin D1 in breast cancer pathogenesis. J Clin Oncol 2005;23(18):4215–24.
McIntosh GG, Anderson JJ, Milton I, Steward M, Parr AH, Thomas MD, et al. Determination of the prognos- tic value of cyclin D1 overexpression in breast cancer. Oncogene 1995;11(5):885–91.
Michalides R, Hageman P, van Tinteren H, Houben L, Wientjens E, Klompmaker R, et al. A clinicopathologi- cal study on overexpression of cyclin D1 and of p53 in a series of 248 patients with operable breast cancer. Br J Cancer 1996;73(6):728–34.
Gillett C, Smith P, Gregory W, Richards M, Millis R, Peters G, et al. Cyclin D1 and prognosis in human breast cancer. Int J Cancer 1996;69(2):92–9.
Van Diest PJ, Michalides RJ, Jannink L, van der Valk P, Peterse HL, de Jong JS, et al. Cyclin D1 expression in invasive breast cancer. Correlations and prognostic
of the patients. value. Am J Pathol 1997;150(2):705,11.
Umekita Y, Ohi Y, Sagara Y, Yoshida H. Overexpres- sion of cyclinD1 predicts for poor prognosis in es- trogen receptor-negative breast cancer patients. Int J Cancer 2002;98(3):415–8.
De Vita VT, Hellman S, Rosenberg SA, eds. Can- cer: Principles & Practice of Oncology, Philadelphia, PA: Lippincott Williams Wilkins, Seventh Edition 2005;73–164.
Bates S, Peters G. Cyclin D1 as a cellular proto-onco- gene. Semin Cancer Biol 1995;6(2):73–82.
Weinstat-Saslow D, Merino MJ, Manrow RE, Law- rence JA, Bluth RF, Wittenbel KD, et al. Overexpres- sion of cyclin D mRNA distinguishes invasive and in situ breast carcinomas from non-malignant lesions. Nat Med 1995;1(12):1257–60.
Pelosio P, Barbareschi M, Bonoldi E, Marchetti A, Verderio P, Caffo O et al. Clinical significance of cyclin D1 expression in patients with node-positive breast carcinoma treated with adjuvant therapy. Ann Oncol 1996;7(7):695–703.
Seshadri R, Lee CS, Hui R, McCaul K, Horsfall D J, Sutherland RL. Cyclin DI amplification is not associ- ated with reduced overall survival in primary breast cancer but may predict early relapse in patients with features of good prognosis. Clin Cancer Res 1996;2(7):1177–84.
Xu XL, Chen SZ, Chen W, Zheng WH, Xia XH, Yang HJ, et al. The impact of cyclin D1 overexpression on the prognosis of ER-positive breast cancers: a meta- analysis. Breast Cancer Res Treat 2013;139(2):329–39.
Warwick J, Tabàr L, Vitak B, Duffy SW. Time-depen- dent effects on survival in breast carcinoma: results of 20 years of follow-up from the Swedish Two-County Study. Cancer 2004;100(7):1331–6.
Debled M, MacGrogan G, Brouste V, Mathoulin-Pe- lissier S, Durand M, Mauriac L. Prognostic factors of early distant recurrence in hormone receptor-positive, postmenopausal breast cancer patients receiving ad- juvant tamoxifen therapy: results of a retrospective analysis. Cancer 2007;109(11):2197–204.
Nishimukai A, Yagi T, Yanai A, Miyagawa Y, Eno- moto Y, Murase K, et al. High Ki-67 Expression and Low Progesterone Receptor Expression Could Inde- pendently Lead to a Worse Prognosis for Postmeno- pausal Patients With Estrogen Receptor-Positive and HER2-Negative Breast Cancer. Clin Breast Cancer 2015;15(3):204–11.
Sun JY, Wu SG, Li FY, Lin HX, He ZY. Progesterone receptor loss identifies hormone receptor-positive and HER2-negative breast cancer subgroups at higher risk of relapse: a retrospective cohort study. Onco Targets Ther 2016;9:1707–13.
Jirström K, Stendahl M, Rydén L, Kronblad A, Bendahl PO, Stål O, et al. Adverse effect of adjuvant tamoxifen in premenopausal breast cancer with cyclin D1 gene amplification. Cancer Res 2005;65 (17):8009–16.
Ahnström M, Nordenskjöld B, Rutqvist LE, Skoog L, Stål O. Role of cyclin D1 in ErbB2-positive breast can- cer and tamoxifen resistance. Breast Cancer Res Treat
Finn RS, Crown JP, Lang I, Boer K, Bondarenko IM, Kulyk SO, et al. The cyclin-dependent kinase 4/6 in- hibitor palbociclib in combination with letrozole ver- sus letrozole alone as first-line treatment of oestrogen receptor-positive, HER2-negative, advanced breast cancer (PALOMA-1/TRIO-18): a randomised phase 2 study. Lancet Oncol 2015;16(1):25–35.